ReviewAdvanced drug delivery reviews2021
Clinical translation of immunomodulatory therapeutics.
Review in Advanced drug delivery reviews, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 25 citations in OpenAlex.
- mRNA-based therapeutics in lung Cancer: Mechanisms, applications, and translational challenges.Journal, genetic engineering & biotechnology · 2026Review
- Non-Drug therapeutic strategies to combat antimicrobial resistance in livestock: a review.Molecular biology reports · 2026Review
- First-In-Human Trial of Encapsulated Cells Constitutively Expressing Localized IL2 in Patients with High-Grade Serous Ovarian Carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Endophyte-mediated biosynthesis of biogenic nanoparticles: mechanisms and biomedical applications.Archives of microbiology · 2026Review
- Artificial intelligence and machine learning in immunosenescence: from biomarker discovery to clinical translation.Frontiers in aging · 2026Review
- First-In-Human Trial of Encapsulated Cell-Based Protein Producers for Localized IL-2 in Patients with High-Grade Serous Ovarian Carcinoma.medRxiv : the preprint server for health sciences · 2025Article
- Combined IFN-γ and TNF-α treatment enhances the susceptibility of breast cancer cells and spheroids to Natural Killer cell-mediated killing.Cell death & disease · 2025Article
- Immunological Factors in Recurrent Pregnancy Loss: Mechanisms, Controversies, and Emerging Therapies.Biology · 2025Review
- Smart biomaterials: as active immune modulators to shape pro-regenerative microenvironments.Frontiers in cell and developmental biology · 2025Review
- Mechanisms and Research Progress of Magnetic Nanoparticles in Modulating Neural Plasticity for Neuroregeneration.Nanotechnology, science and applications · 2025Review
- Future applications of host direct therapies for infectious disease treatment.Frontiers in immunology · 2024Review
- Control of the post-infarct immune microenvironment through biotherapeutic and biomaterial-based approaches.Drug delivery and translational research · 2023Review
- Self-assembling peptides as immunomodulatory biomaterials.Frontiers in bioengineering and biotechnology · 2023Review
- Applications of Extracellular Vesicles in Nervous System Disorders: An Overview of Recent Advances.Bioengineering (Basel, Switzerland) · 2022Review
- Exosomes as CNS Drug Delivery Tools and Their Applications.Pharmaceutics · 2022Review
- Evolution of drug delivery systems: From 1950 to 2020 and beyond.Journal of controlled release : official journal of the Controlled Release Society · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Immunomodulatory therapeutics represent a unique class of drug products that have tremendous potential to rebalance malfunctioning immune systems and are quickly becoming one of the fastest-growing areas in the pharmaceutical industry. For these drugs to become mainstream medicines, they must provide greater therapeutic benefit than the currently used treatments without causing severe toxicities. Immunomodulators, cell-based therapies, antibodies, and viral therapies have all achieved varying amounts of success in the treatment of cancers and/or autoimmune diseases. However, many challenges related to precision dosing, off-target effects, and manufacturing hurdles will need to be addressed before we see widespread adoption of these therapies in the clinic. This review provides a perspective on the progress of immunostimulatory and immunosuppressive therapies to date and discusses the opportunities and challenges for clinical translation of the next generation of immunomodulatory therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.